138 related articles for article (PubMed ID: 3675680)
1. Pharmacokinetics of isosorbide mononitrate in a new sustained release oral form in comparison with a conventional formulation.
Gandini R; Cunietti E; Assereto R; Castoldi D; Tofanetti O; Baggio E
Arzneimittelforschung; 1987 Jul; 37(7):836-9. PubMed ID: 3675680
[TBL] [Abstract][Full Text] [Related]
2. [Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers].
Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
Yao Xue Xue Bao; 1998 May; 33(5):373-8. PubMed ID: 12017006
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations.
Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF
Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation].
Skutta T; Böttcher B; Brandt L
Arzneimittelforschung; 1989 Apr; 39(4):507-11. PubMed ID: 2751738
[TBL] [Abstract][Full Text] [Related]
5. Single and multiple dose pharmacokinetic studies of oral sustained release and non-sustained release formulations of isosorbide-5-mononitrate in healthy volunteers.
Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
Arzneimittelforschung; 1998 Jun; 48(6):641-5. PubMed ID: 9689420
[TBL] [Abstract][Full Text] [Related]
6. Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group.
Cleophas TJ; Niemeyer MG; Zwinderman AH; van der Wall EE
Angiology; 2000 Aug; 51(8):631-8. PubMed ID: 10959515
[TBL] [Abstract][Full Text] [Related]
7. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations.
Vree TB; Dammers E; Valducci R
Int J Clin Pharmacol Ther; 2004 Aug; 42(8):463-72. PubMed ID: 15366327
[TBL] [Abstract][Full Text] [Related]
8. [Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations].
Scheidel B; Blume H; Stenzhorn G; Siewert M; Babej-Dölle RM
Arzneimittelforschung; 1991 Mar; 41(3):212-8. PubMed ID: 1867657
[TBL] [Abstract][Full Text] [Related]
9. Performance of a slow-release formulation of isosorbide-5-mononitrate (ISMO retard).
Neugebauer G; Akpan W; Stemmle B; Jaeger H; Mosberg H; Lutz D
Int J Clin Pharmacol Ther Toxicol; 1989 Jan; 27(1):34-8. PubMed ID: 2744904
[TBL] [Abstract][Full Text] [Related]
10. Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate.
Parker JO
Can J Cardiol; 1991 Apr; 7(3):125-30. PubMed ID: 2044014
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate.
Laufen H; Leitold M; Wildfeuer A
Arzneimittelforschung; 1988 Sep; 38(9):1336-41. PubMed ID: 3223973
[TBL] [Abstract][Full Text] [Related]
12. A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate.
Smith D; Aldrich W; Dey M; Enever R; Warner R; Weierstall R
Drug Metab Dispos; 1990; 18(4):429-34. PubMed ID: 1976063
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation.
Kosoglou T; Patrick JE; Cohen A; Radwanski E; Christopher D; Affrime MB
Clin Ther; 1995; 17(2):241-51. PubMed ID: 7614524
[TBL] [Abstract][Full Text] [Related]
14. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D
Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739
[TBL] [Abstract][Full Text] [Related]
15. [Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate].
Muck B; Bonn R; Rietbrock N
Arzneimittelforschung; 1989 Oct; 39(10):1274-6. PubMed ID: 2610720
[TBL] [Abstract][Full Text] [Related]
16. Sustained-release isosorbide mononitrate (50 mg): optimization of a once-daily dosage form for long-term treatment of angina pectoris.
Bonn R
Am J Cardiol; 1988 Mar; 61(9):12E-14E. PubMed ID: 3348135
[TBL] [Abstract][Full Text] [Related]
17. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].
Geigenberger A; Degen J; Maier-Lenz H
Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839
[TBL] [Abstract][Full Text] [Related]
18. Plasma concentrations of isosorbide dinitrate after oral administration of a sustained-release formulation to human subjects.
Assinder DF; Chasseaud LF; Hunter JO; Jung RJ; Taylor T
Arzneimittelforschung; 1977; 27(1):156-8. PubMed ID: 576817
[TBL] [Abstract][Full Text] [Related]
19. Anti-anginal and anti-ischemic efficacy of conventional and slow release formulations of isosorbide-5-mononitrate in angina pectoris.
Thadani U
Z Kardiol; 1985; 74 Suppl 4():21-4. PubMed ID: 4096067
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the initial hemodynamic effects of immediate-release versus sustained-release isosorbide-5-mononitrate following single oral doses.
Trenk D; Hinder M; Stengele E; Bonn R; Jähnchen E
J Clin Pharmacol; 2000 Feb; 40(2):168-76. PubMed ID: 10664923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
